Private Equity 24 Hours

Last updated: June 6, 2026, 5:31 AM ET

Fundraising & New Vehicles Targeted $8.5bn fundraising underscored the continued appetite for mid‑market buyouts as TJC launched its Resolute Fund VII, which will focus on North‑American companies generating $50‑250m in EBITDA. The same week, raised $2.43bn in IPO proceeds highlighted private‑equity sponsors Advent International and ADIA capitalising on market enthusiasm for industrial tech, with gas‑engine maker Innio soaring 23% on debut. Meanwhile, expanded forward‑flow commitment saw Canada Pension Plan Investment Board increase its partnership with consumer‑lending platform Affirm to $1.7bn, with an optional lift to $2.2bn, reinforcing the trend of institutional investors locking in fintech exposure.

Strategic Acquisitions Acquired Total Safety Supplies marked Mill Point’s entry into the industrial‑products distribution space, adding a niche safety‑equipment portfolio to its platform. In Europe, took minority stake in Twin Pack gave Consilium a foothold in automated secondary packaging, a segment benefiting from e‑commerce volume growth. Across the Atlantic, sold Walor Precision Turning demonstrated Mutares’ exit strategy in automotive components, as French sponsor Reed Capital moved to acquire the precision‑turning business for an undisclosed sum, signalling confidence in niche manufacturing carve‑outs.

Cross‑Border Asset Management Deals Negotiated $467m acquisition positioned Allianz Global Investors to absorb UOB Asset Management, edging out rivals KKR and Amundi and expanding its presence in Southeast Asia’s growing wealth‑management market. In the UK, snapped up Net Natives added a student‑enrollment marketing specialist to Renovus‑backed Education Dynamics, enhancing its education‑services platform ahead of the sector’s post‑pandemic expansion. Simultaneously, kept door ajar for bidders indicated Oxford Bio Medica’s openness to a take‑private offer after rebuffing EQT, suggesting that valuation gaps remain a hurdle for biotech consolidations.

Sector‑Specific Capital Flows Targeted substance‑use care assets highlighted Warburg Pincus, Frazier Healthcare Partners, Lee Equity and Sheridan as they each secured stakes in treatment facilities, reflecting private equity’s shift toward high‑margin healthcare niches. In legal tech, investors poured billions into plaintiff‑side AI while defense‑side solutions lag, prompting funds to scout the next wave of litigation‑tech opportunities. The broader venture ecosystem also saw a surge in megadeals, with megadeals proliferating across AI and space tech illustrating the capital intensity of frontier technologies that private equity may later target for later‑stage roll‑ups.

Governance & Benchmarking Scrutiny Addressed benchmark relevance as Florida’s $219bn pension fund advisory council debated the adequacy of private‑equity performance indices, a dialogue that could reshape reporting standards for large institutional investors. The conversation dovetailed with a viral VC horror‑story thread on X, where founders aired grievances about term‑sheet rigidity and governance demands, signalling potential pressure on private‑equity sponsors to refine sponsor‑founder dynamics.

Leadership Moves Impacting Deal Flow Exited Microsoft board as Reid Hoffman transitioned to full‑time leadership of AI‑driven drug‑discovery startup Manus, a shift that may free board capacity for deeper engagement with biotech initiatives and signal heightened founder involvement in portfolio companies. Collectively, these developments illustrate a private‑equity landscape that remains aggressive in fundraising, selective in strategic acquisitions, and increasingly attentive to sector‑specific opportunities and governance expectations.